Overview
Hepatitis C virus (HCV) is a single-stranded RNA virus belonging to the Flaviviridae family and is a major cause of chronic liver disease worldwide. HCV infection accounts for approximately 60–70% of all cases of chronic hepatitis. The virus is hepatotropic and primarily affects liver tissue, leading to progressive liver damage if left untreated.
Hepatitis C virus (HCV) DNA PCR (Qualitative) is a molecular diagnostic test used to detect the presence or absence of HCV RNA in blood. It is considered the gold standard for confirming active HCV infection. Unlike antibody tests, qualitative PCR directly detects viral RNA, making it highly useful for early diagnosis, confirmation of active disease, and assessment of infectivity.
Acute Hepatitis C virus (HCV) infection is often asymptomatic or associated with non-specific symptoms and therefore frequently goes undiagnosed. However, a significant proportion of infected individuals, ranging from 60–85%, develop chronic infection. Chronic HCV infection is associated with an increased risk of cirrhosis, end-stage liver disease, and hepatocellular carcinoma, highlighting the importance of early and accurate molecular testing. HCV – DNA – PCR – Qualitative
Symptoms
Many individuals with HCV infection do not exhibit symptoms, especially during the early or acute phase. As a result, infection often remains undetected for long periods.
When symptoms do occur, they are generally non-specific and related to liver inflammation. These may include fever, fatigue, loss of appetite, nausea, vomiting, abdominal pain, and jaundice. Due to the silent nature of the disease, laboratory testing plays a critical role in identifying infected individuals before the onset of advanced liver damage.
Causes
Hepatitis C virus (HCV) infection occurs through parenteral exposure to infected blood or blood products. The most common routes of transmission include transfusion of infected blood, sharing needles or other injection equipment, and unsafe medical practices.
Healthcare workers who are frequently exposed to blood or body fluids are also at risk. Vertical transmission from mother to newborn can occur, although less commonly than with hepatitis B. There is currently no vaccine available for hepatitis C, making prevention and early detection especially important.
Risk Factors
Individuals at higher risk of Hepatitis C virus (HCV) infection include those with a history of blood product transfusions, injection drug use, or sharing needles and syringes. Newborns born to HCV-infected mothers are also considered at risk and require testing.
Healthcare workers, hemodialysis patients, immunocompromised individuals, and people undergoing frequent medical or surgical procedures are additional high-risk groups. In recent years, HCV qualitative PCR testing has become routine in hospital admissions, preoperative evaluations, and antenatal care to identify infection early and reduce transmission.
Prevention
Prevention of HCV infection relies on early diagnosis, strict infection control practices, and safe handling of blood and medical equipment. Since no vaccine is available, screening of high-risk individuals and blood products is essential.
Avoidance of needle sharing, safe transfusion practices, and adherence to universal precautions in healthcare settings significantly reduce transmission. Early detection through qualitative PCR allows timely initiation of treatment, which helps prevent disease progression and reduces the risk of long-term complications.
Clinical and Diagnostic Importance
HCV DNA PCR qualitative testing offers several advantages, including rapid reporting, high sensitivity, and high specificity. The test can detect HCV RNA as early as 1–2 weeks after infection, well before antibodies develop, which typically takes 6–9 weeks.
The test confirms active infection, differentiates active infection from resolved disease, and helps identify relapse or re-infection after treatment. However, qualitative PCR cannot quantify viral load and is not suitable for monitoring therapy response. Low viral load may result in false-negative results, and advanced laboratory equipment and trained personnel are required.
Despite these limitations, HCV DNA PCR qualitative testing remains an essential diagnostic tool for confirming HCV infection, guiding clinical decisions, and improving patient outcomes when used alongside other serological and molecular tests.
